Secondary prevention of coronary heart disease

Archives of Physical Medicine and Rehabilitation

Volumn 79, Issue 8, 1998, Pages 1006-1017

  Zafari, A Maziar ^a   Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CAPTOPRIL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ESTROGEN; GESTAGEN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; NICOTINIC ACID; PHENPROCOUMON; PRAVASTATIN; PROPRANOLOL; SIMVASTATIN; SULFINPYRAZONE; UNINDEXED DRUG; WARFARIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING CESSATION;

EID: 0031870479     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(98)90103-4     Document Type: Review

References (99)

1. American Heart Association. Heart and Stroke Facts. 1996 Statistical Supplement. Dallas (TX): American Heart Association; 1995.
2. Kannel WB, Wilson PWF. An update on coronary risk factors. Med Clin North Am 1995;79:951-71.
3. Fuster V, Pearson TA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957-1047.
4. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1996;94: 2341-50.
5. Smith SC Jr. Risk-reduction therapy: the challenge to change. Circulation 1996;93:2201-11.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50, 310-8.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
8. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
10. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-9.
11. Department of Health and Human Services. The health consequences of smoking: cardiovascular disease: a report of the Surgeon General. Washington (DC): US Department of Health and Human Services, Public Health Service, Office on Smoking and Health. DHHS Publication No. (PHS) 84-50204; 1983.
12. Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (CDC) 90-8416; 1990.
13. Williams RR, Hopkins PN, Wu LL, Schumacher C, Hunt SC. Evaluating family history to prevent early coronary heart disease. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in preventive cardiology. Dallas (TX): American Heart Association; 1994. p. 93-106.
14. Hopkins PN, Williams RR, Hunt SC. Magnified risks from cigarette smoking for coronary prone families in Utah. West J Med 1984;141:196-202.
15. Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Wilhelmsen L. Smoking and myocardial infarction. Lancet 1975;1:415-20.
16. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO, et al, for the CASS Investigators. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. J Am Coll Cardiol 1992;20:287-94.
17. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997;336: 755-61.
18. Taylor CB, Houston-Miller N, Killen JD, De Busk RF. Smoking cessation after acute myocardial infarction. Effects of a nurse-managed intervention. Ann Intern Med 1990;113:118-23.
19. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Smoking cessation. Clinical practice guidelines No 18. Rockville (MD): US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 96-0692; April 1996.
20. Tsevat J. Impact and cost-effectiveness of smoking interventions. Am J Med 1992;93:43S-47S.
21. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993;22:1697-702.
22. Deedwania PC. Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. Med Clin North Am 1995;79:973-98.
23. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al. Regular physical exercise and low fat diet. Effects on progression of coronary artery disease. Circulation 1992;86:1-11.
24. Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303-10.
25. Hjermann I, Holme I, Leren P. Oslo Study Diet and Antismoking Trial. Results after 102 months. Am J Med 1986;80:7-11.
26. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
27. Fletcher GF, Blair SN, Blumenthal J, Caspersen C, Chaitman B, Epstein S, et al. Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992;86:340-4.
28. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr., et al. An overview of randomized clinical trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.
29. Oldridge N, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.
30. Wenger NK, Froelicher ES, Smith LK, Ades PA, Berra K, Blumenthal JA, et al. Cardiac rehabilitation. Clinical practice guideline No. 17. Rockville (MD): US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, AHCPR Publication No. 96-0672; October 1995.
31. Oldridge N, Guyatt G, Jones N, Crowe J, Singer J, Feeny D, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol 1991;67:1084-9.
32. Oldridge N, Furlong W, Feeny D, Torrance G, Guyatt G, Crowe J. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol 1993;72:154-61.
33. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
34. Quinn TG, Alderman EL, McMillan A, Haskell W, for the SCRIP Investigators. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: The Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cardiol 1994;24:900-8.
35. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
36. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.
37. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323: 1112-9.
38. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87: 1781-91.
39. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1382-9.
40. Sacks FM, Rouleau JL, Moye LA, Pfeffer MA, Warnica JW, Arnold JM, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995;75: 621-3.
41. Canner PL, Berge KG, Wenger NK, Stander J, Friedman L, Prineas RJ, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8: 1245-55.
42. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 1971;4:767-75.
43. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a Research Committee of the Scottish Society of Physicians. BMJ 1971;4:775-84.
44. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
45. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin J-T, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
46. Stewart BF, Brown BG, Zhao X-Q, Hilger LA, Sniderman AD, Dowdy A, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994;23:899-906.
47. Byington RP, Furberg CD, Grouse JR III, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995;76:54C-59C.
48. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandianvian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
49. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92: 2419-25.
50. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-445.
51. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265: 1145-51.
52. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.
53. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989;13:I2-I12.
54. Maseri A, Crea KF, Cianflone D. Myocardial ischemia caused by distal coronary vasoconstriction. Am J Cardiol 1992;70:1602-5.
55. Reddy KG, Nair RN, Sheehan HM, Hodgson JMcB. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994;23:833-43.
56. Kaplan NM. The deadly quartet. Arch Intern Med 1989;149: 1514-20.
57. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-63.
58. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G, on behalf of the Advisory Committee. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259:1976-82.
59. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
60. Heller RF, Chinn S, Pedoe HDT, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ 1984;288:1409-11.
61. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
62. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296:320-31.
63. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997; 77:333-7.
64. Chesebro JH, Webster MWI, Zolhelyi P, Roche PC. Antithrombotic therapy and progression of coronary artery disease. Circulation 1992;86 Suppl III: 100-11.
65. Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995; 273:965-7.
66. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
67. Smith P, Arnesen H, Abdelnoor M. Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 1992;152:993-7.
68. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
69. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980;2:989-94.
70. Meijer A, Verbeugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993;87:1524-30.
71. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I: mortality results. JAMA 1982;247:1707-14.
72. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993;118:99-105.
73. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, et al. Consensus Panel Statement. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2-4.
74. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE, et al., on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327: 669-77.
75. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
76. Vantrimpont P, Rouleau JL, Wun C-C, Ciampi A, Klein M, Sussex B, et al, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997;29:229-36.
77. Barrett-Connor E. Estrogen and coronary heart disease. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in preventive cardiology. Dallas (TX): American Heart Association; 1994. p. 249-54.
78. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels. Lancet 1959;2:690-4.
79. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995;92:5-8.
80. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
81. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JA, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
82. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
83. Jialal I, Scaccini C. Antioxidants and atherosclerosis. Curr Opin Lipid 1992;3:324-8.
84. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
85. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
86. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
87. Pearson T, Rapaport E, Criqui M, Furberg C, Fuster V, Hiratzka L, et al. Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. Circulation 1994;90: 3125-33.
88. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
89. Fuster V, Vorchheimer DA. Prevention of atherosclerosis in coronary-artery bypass grafts. N Engl J Med 1997;336:212-3.
90. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
91. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholesteryramine on progression of coronary atherosclerosis: results of NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24.
92. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts [published erratum appears in JAMA 1988;259: 2698]. JAMA 1987;257:3233-40.
93. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-17.
94. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
95. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
96. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994;344:1182-86.
97. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
98. Oliver MF, DeFeyler PJ, Lubsen J, Pocock S, Simoons M, et al. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS) [published erratum appears in Lancet 1994;344:762]. Lancet 1994;344:633-38.
99. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.